Icure Pharmaceutical Incorporation (175250) - Total Liabilities

Latest as of June 2025: ₩80.55 Billion KRW ≈ $54.59 Million USD

Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has total liabilities worth ₩80.55 Billion KRW (≈ $54.59 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Icure Pharmaceutical Incorporation (175250) cash conversion ratio to assess how effectively this company generates cash.

Icure Pharmaceutical Incorporation - Total Liabilities Trend (2015–2024)

This chart illustrates how Icure Pharmaceutical Incorporation's total liabilities have evolved over time, based on quarterly financial data. Check 175250 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Icure Pharmaceutical Incorporation Competitors by Total Liabilities

The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their total liabilities.

Company	Country	Total Liabilities
American Creek Resources Ltd V:AMK	Canada	CA$30.45K
Copenhagen Capital A/S CO:CPHCAP-ST	Denmark	Dkr649.40 Million
Electra Battery Materials Corp NASDAQ:ELBM	USA	$100.05 Million
Space Com TA:SCC	Israel	ILA567.03 Million
iBio, Inc. Common Stock NASDAQ:IBIO	USA	$7.83 Million
Electra Battery Materials Corp V:ELBM	Canada	CA$100.05 Million
Nahar Industrial Enterprises Limited NSE:NAHARINDUS	India	Rs6.90 Billion
Wisekey International Holding AG NASDAQ:WKEY	USA	$28.43 Million

Liability Composition Analysis (2015–2024)

This chart breaks down Icure Pharmaceutical Incorporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Icure Pharmaceutical Incorporation market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.71	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.61	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.62	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Icure Pharmaceutical Incorporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Icure Pharmaceutical Incorporation (2015–2024)

The table below shows the annual total liabilities of Icure Pharmaceutical Incorporation from 2015 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩72.62 Billion ≈ $49.22 Million	-31.84%
2023-12-31	₩106.54 Billion ≈ $72.20 Million	-20.76%
2022-12-31	₩134.45 Billion ≈ $91.11 Million	+12.33%
2021-12-31	₩119.69 Billion ≈ $81.11 Million	+44.22%
2020-12-31	₩82.99 Billion ≈ $56.24 Million	-29.82%
2019-12-31	₩118.27 Billion ≈ $80.15 Million	+225.73%
2018-12-31	₩36.31 Billion ≈ $24.61 Million	-0.32%
2017-12-31	₩36.43 Billion ≈ $24.69 Million	+149.76%
2016-12-31	₩14.58 Billion ≈ $9.88 Million	-27.76%
2015-12-31	₩20.19 Billion ≈ $13.68 Million	--

About Icure Pharmaceutical Incorporation

KQ:175250 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$54.96 Million

₩81.09 Billion KRW

Market Cap Rank

#21528 Global

#1388 in Korea

Share Price

₩2170.00

Change (1 day)

+11.91%

52-Week Range

₩1763.00 - ₩2170.00

All Time High

₩23730.97